Promising new cocktail aims to shrink lung tumors
NCT ID NCT07538258
First seen Apr 20, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study tests a new combination of drugs and radiation as a first treatment for people with limited-stage small cell lung cancer (LS-SCLC) that cannot be removed by surgery. The treatment includes an immunotherapy (benmelstobart), a drug that cuts off tumor blood supply (anlotinib), standard chemotherapy, and chest radiation. The goal is to see how many patients' tumors shrink or disappear. The study will enroll 27 adults aged 18 to 75 and is expected to start in March 2026.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.